Abstract
Inhibitor of proteasome, bortezomib (BOR), although highly active in vitro, showed unexpectedly low efficacy in vivo in patients with B-CLL when used alone. We studied the in vitro cytotoxic effects of BOR in combination with anti-CD20 (rituximab, RIT) or anti-CD52 (campath, CAM) monoclonal antibodies on B-CLL cells. Both BOR+RIT and BOR+CAM combinations exerted additive cytotoxicity, triggering caspase-dependent apoptosis. The treatment significantly modified expression of several apoptosis-regulating proteins, including upregulation of Bax or downregulation of Bcl-2 and Mcl-1 by BOR+RIT, as well as downregulation of Bcl-2 and XIAP by BOR+CAM. These data suggest the feasibility of concomitant use of those agents for the treatment of B-CLL patients.
References
Nov 21, 1998·Immunology·W RowanS J Brett
Jun 3, 1999·British Journal of Haematology·P MasdehorsJ Delic
Jan 25, 2002·Blood·John C ByrdJohn C Reed
Nov 9, 2002·Blood·Nicholas MitsiadesKenneth C Anderson
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiSteven L Soignet
Dec 11, 2002·British Journal of Haematology·Joseè GolayMartino Introna
May 6, 2003·Oncogene·Grant DewsonGerald M Cohen
Apr 8, 2004·Leukemia Research·Chadi NabhanMartin S Tallman
Apr 8, 2004·Leukemia Research·Clive S ZentSteven A Schichman
Apr 9, 2004·Blood·Dharminder ChauhanKenneth C Anderson
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xin-Yan PeiSteven Grant
Jun 19, 2004·Leukemia Research·Todd W KelleyEric D Hsi
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter F BrossRichard Pazdur
Jul 1, 2004·Annals of Medicine·Paul G RichardsonKenneth Anderson
Aug 17, 2004·Annals of Hematology·Michael StanglmaierMichael Hallek
Dec 29, 2004·Leukemia & Lymphoma·Piotr SmolewskiTadeusz Robak
Mar 25, 2005·Oncogene·Ali R Jazirehi, Benjamin Bonavida
Apr 9, 2005·European Journal of Haematology·Markus DuechlerPiotr Smolewski
Citations
Nov 11, 2006·Leukemia·A NencioniP Brossart
Dec 2, 2011·Journal of Hematology & Oncology·Shiloh M MartinJoseph M Tuscano
Apr 27, 2012·Patient Preference and Adherence·Danielle M Brander, Anne W Beaven
Dec 28, 2007·Blood·Feng-Ting LiuLi Jia
Dec 28, 2007·Blood·Samir G AgrawalLi Jia
Dec 16, 2006·Leukemia & Lymphoma·Paweł RobakPiotr Smolewski
Sep 16, 2011·Leukemia & Lymphoma·Tri-Hung NguyenSrinivas Shankara
Apr 18, 2009·Leukemia & Lymphoma·Claudia Stolz, Martin Schuler
Jul 5, 2011·The Lancet Oncology·Bertrand CoiffierUNKNOWN LYM-3001 study investigators
Sep 1, 2009·Clinical Lymphoma & Myeloma·John P LeonardJohn W Sweetenham
Aug 26, 2010·British Journal of Haematology·Jorge E RomagueraAndre Goy
Oct 30, 2010·Clinical Lymphoma, Myeloma & Leukemia·Michael E WilliamsJohn P Leonard
Sep 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sven de VosAnthony L Boral
Apr 24, 2013·Therapeutic Advances in Hematology·Michele MerliFrancesco Passamonti
May 4, 2018·Cancer·Jorge E RomagueraAndre Goy
Jan 29, 2008·Cancer·Wanlong MaMaher Albitar
May 15, 2012·International Journal of Oncology·Lian-Nv QiuWei-Xiao Hu
Mar 12, 2017·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Yang ZhaoYong Zhao
Jun 5, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven P TreonAshraf Badros
Aug 5, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John J Wright